Sandbox:Roukoz: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 3: Line 3:
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases
| colspan="6" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations'''
| colspan="6" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations'''
! colspan="7" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings
! colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings
|-
|-
Line 10: Line 10:
|-
|-
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology
|-  
|-  
Line 22: Line 21:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab 2
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab 2
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab 3
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab 3
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging 1
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging 2
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging 3
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Cutaneous squamous cell carcinoma'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Cutaneous squamous cell carcinoma'''
Line 33: Line 29:
| style="background: #F5F5F5; padding: 5px;" |Hyperkeratotic
| style="background: #F5F5F5; padding: 5px;" |Hyperkeratotic
| style="background: #F5F5F5; padding: 5px;" |Increased size
| style="background: #F5F5F5; padding: 5px;" |Increased size
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 50: Line 43:
| style="background: #F5F5F5; padding: 5px;" |Single pink, red, or purple shiny bump
| style="background: #F5F5F5; padding: 5px;" |Single pink, red, or purple shiny bump
| style="background: #F5F5F5; padding: 5px;" |Painless
| style="background: #F5F5F5; padding: 5px;" |Painless
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 64: Line 54:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Lump that has been rapidly growing over the past weeks
| style="background: #F5F5F5; padding: 5px;" |Lump that has been rapidly growing over the past weeks
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 84: Line 71:
| style="background: #F5F5F5; padding: 5px;" |Usually have an asymmetrical shape with an irregular border
| style="background: #F5F5F5; padding: 5px;" |Usually have an asymmetrical shape with an irregular border
| style="background: #F5F5F5; padding: 5px;" |Red, nonspecific lesion with slightly elevated borders
| style="background: #F5F5F5; padding: 5px;" |Red, nonspecific lesion with slightly elevated borders
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 100: Line 84:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Coarse scale lesion
| style="background: #F5F5F5; padding: 5px;" |Coarse scale lesion
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 117: Line 98:
| style="background: #F5F5F5; padding: 5px;" |Scaly patch
| style="background: #F5F5F5; padding: 5px;" |Scaly patch
| style="background: #F5F5F5; padding: 5px;" |Erythematous lesion
| style="background: #F5F5F5; padding: 5px;" |Erythematous lesion
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 134: Line 112:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Pearly papule with telangiectasias
| style="background: #F5F5F5; padding: 5px;" |Pearly papule with telangiectasias
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 150: Line 125:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Other sites lungs, liver, brain, skin, or bone.
| style="background: #F5F5F5; padding: 5px;" |Other sites lungs, liver, brain, skin, or bone.
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 162: Line 134:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Benign Skin Lesions'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Benign Skin Lesions'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 182: Line 151:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Yellow-nodule
| style="background: #F5F5F5; padding: 5px;" |Yellow-nodule
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 195: Line 161:
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Rhabdomyosarcoma'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Rhabdomyosarcoma'''
| style="background: #F5F5F5; padding: 5px;" |Bulging of the eye or a swollen eyelid
| style="background: #F5F5F5; padding: 5px;" |Bulging of the eye or a swollen eyelid
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 216: Line 179:
| style="background: #F5F5F5; padding: 5px;" |Erythema
| style="background: #F5F5F5; padding: 5px;" |Erythema
| style="background: #F5F5F5; padding: 5px;" |less pigmentation, and tend to be somewhat smaller in size.
| style="background: #F5F5F5; padding: 5px;" |less pigmentation, and tend to be somewhat smaller in size.
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 228: Line 188:
| style="background: #F5F5F5; padding: 5px;" |Hard lesion
| style="background: #F5F5F5; padding: 5px;" |Hard lesion
| style="background: #F5F5F5; padding: 5px;" |Itchy lumps
| style="background: #F5F5F5; padding: 5px;" |Itchy lumps
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 247: Line 204:
| style="background: #F5F5F5; padding: 5px;" |Eczema-like rash of the skin
| style="background: #F5F5F5; padding: 5px;" |Eczema-like rash of the skin
| style="background: #F5F5F5; padding: 5px;" |Around the genital regions of males and females.
| style="background: #F5F5F5; padding: 5px;" |Around the genital regions of males and females.
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 262: Line 216:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Waxy, "stuck on," often hyperkeratotic appearance
| style="background: #F5F5F5; padding: 5px;" |Waxy, "stuck on," often hyperkeratotic appearance
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 278: Line 229:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Verrucous lesion
| style="background: #F5F5F5; padding: 5px;" |Verrucous lesion
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 296: Line 244:
| style="background: #F5F5F5; padding: 5px;" |Red, dome-shaped
| style="background: #F5F5F5; padding: 5px;" |Red, dome-shaped
| style="background: #F5F5F5; padding: 5px;" |Friable papule with a collarette of scale
| style="background: #F5F5F5; padding: 5px;" |Friable papule with a collarette of scale
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 310: Line 255:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |multiple, red- to brown-colored, small papules that  
| style="background: #F5F5F5; padding: 5px;" |multiple, red- to brown-colored, small papules that  
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 329: Line 271:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Coin shaped spots
| style="background: #F5F5F5; padding: 5px;" |Coin shaped spots
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 345: Line 284:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Thick, white, silvery, or red patches of skin
| style="background: #F5F5F5; padding: 5px;" |Thick, white, silvery, or red patches of skin
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 362: Line 298:
| style="background: #F5F5F5; padding: 5px;" |Purulent ulcer
| style="background: #F5F5F5; padding: 5px;" |Purulent ulcer
| style="background: #F5F5F5; padding: 5px;" |Ragged and violaceous border
| style="background: #F5F5F5; padding: 5px;" |Ragged and violaceous border
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 373: Line 306:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Venous stasis ulcers'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Venous stasis ulcers'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 389: Line 319:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Traumatic ulcers'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Traumatic ulcers'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 409: Line 336:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Red scaly patch
| style="background: #F5F5F5; padding: 5px;" |Red scaly patch
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 429: Line 353:
Yellowish, soft, small papules on the face  
Yellowish, soft, small papules on the face  
| style="background: #F5F5F5; padding: 5px;" |Usually on the nose, cheeks, and forehead
| style="background: #F5F5F5; padding: 5px;" |Usually on the nose, cheeks, and forehead
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 443: Line 364:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Red rash
| style="background: #F5F5F5; padding: 5px;" |Red rash
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 459: Line 377:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Red rash
| style="background: #F5F5F5; padding: 5px;" |Red rash
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 475: Line 390:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Erythematous, dome-shaped papule  
| style="background: #F5F5F5; padding: 5px;" |Erythematous, dome-shaped papule  
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 487: Line 399:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Nevus'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Nevus'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 503: Line 412:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Chemical Burns'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Chemical Burns'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 519: Line 425:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Limbal Dermoid'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Limbal Dermoid'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 536: Line 439:
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Benign hereditary intraepithelial dyskeratosis'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Benign hereditary intraepithelial dyskeratosis'''


| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 552: Line 452:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''primary acquired melanosis'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''primary acquired melanosis'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 568: Line 465:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Fibrous xanthoma'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Fibrous xanthoma'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 590: Line 484:
| style="background: #F5F5F5; padding: 5px;" |Inflamed and hyperpigmented
| style="background: #F5F5F5; padding: 5px;" |Inflamed and hyperpigmented
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |On dermatoscopic evaluation, presence of horned cysts and hairpin-shaped blood vessels
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 606: Line 497:
| style="background: #F5F5F5; padding: 5px;" |Reddened, yellowish-tan color of lesions  
| style="background: #F5F5F5; padding: 5px;" |Reddened, yellowish-tan color of lesions  
| style="background: #F5F5F5; padding: 5px;" |Slightly raised bumps
| style="background: #F5F5F5; padding: 5px;" |Slightly raised bumps
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 617: Line 505:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Cutaneous fungal infections'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Cutaneous fungal infections'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 633: Line 518:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Desmoplastic trichoepithelioma'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Desmoplastic trichoepithelioma'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 649: Line 531:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Adnexal carcinoma'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Adnexal carcinoma'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 665: Line 544:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Keratoacanthoma'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Keratoacanthoma'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 681: Line 557:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Darier disease'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Darier disease'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 697: Line 570:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Cutaneous T-cell lymphoma'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Cutaneous T-cell lymphoma'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 720: Line 590:
| style="background: #F5F5F5; padding: 5px;" |Rolled or everted wound margins
| style="background: #F5F5F5; padding: 5px;" |Rolled or everted wound margins
| style="background: #F5F5F5; padding: 5px;" |Bleeding on touch
| style="background: #F5F5F5; padding: 5px;" |Bleeding on touch
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 738: Line 605:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Increased size
| style="background: #F5F5F5; padding: 5px;" |Increased size
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 747: Line 611:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Anogenital'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Anogenital'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 770: Line 631:
| style="background: #F5F5F5; padding: 5px;" |Dome-shaped or crateriform nodules with a central keratotic core
| style="background: #F5F5F5; padding: 5px;" |Dome-shaped or crateriform nodules with a central keratotic core
| style="background: #F5F5F5; padding: 5px;" |Increased size
| style="background: #F5F5F5; padding: 5px;" |Increased size
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |

Revision as of 17:32, 14 February 2019

Diseases Clinical manifestations Para-clinical findings Additional findings
Symptoms Physical examination
Lab Findings Histopathology
Symptom 1 Symptom 2 Symptom 3 Physical exam 1 Physical exam 2 Physical exam 3 Lab 1 Lab 2 Lab 3
Cutaneous squamous cell carcinoma Pain Erythema Indurated Hyperkeratotic Increased size
  • 60 percent of squamous cell carcinomas occur at the site of a previous actinic keratosis
Merkel cell carcinoma Starts on areas of skin exposed to the sun Single pink, red, or purple shiny bump Painless Blue-red, dome-shaped nodule
Nodular malignant melanoma Lump that has been rapidly growing over the past weeks Cells proliferate downwards through the skin (vertical growth)
  • Two-thirds arise in normal skin, the rest in existing moles
  • Genetic component in some cases with a positive family history
Amelanotic melanoma Color usually pink, purple or normal skin color Usually have an asymmetrical shape with an irregular border Red, nonspecific lesion with slightly elevated borders
  • Do not make melanin, so lesions are not pigmented
Basal cell carcinoma Coarse scale lesion
Superficial basal cell carcinoma Scaly patch Erythematous lesion
  • large, hyperchromatic, oval nuclei and little cytoplasm
  • well differentiated and cells appear histologically similar to basal cells of the epidermis
Nodular basal cell carcinoma Pearly papule with telangiectasias
Cutaneous metastases of internal malignancy Other sites lungs, liver, brain, skin, or bone. The most frequent site of metastasis for cutaneous SCC is the regional lymph nodes;
Benign Skin Lesions
Sebaceous cell carcinoma Yellow-nodule Suspected due to evidence of eyelash loss
Rhabdomyosarcoma Bulging of the eye or a swollen eyelid Develops in skeletal muscles usually
Actinic keratoses Pain Hyperkeratosis Erythema less pigmentation, and tend to be somewhat smaller in size.
Prurigo nodules Hard lesion Itchy lumps
Paget disease Eczema-like rash of the skin Around the genital regions of males and females. Similar to mammary paget disease chronic
Inflamed seborrheic keratosis Waxy, "stuck on," often hyperkeratotic appearance
Viral warts Verrucous lesion Caused by HPV
Pyogenic granuloma Rapidly growing Red, dome-shaped Friable papule with a collarette of scale
Bowenoid papulosis multiple, red- to brown-colored, small papules that
  • primarily arise on genitals
  • induced by human papillomavirus (HPV) infection
Nummular eczema Itchy lesions Coin shaped spots Chronic condition
Psoriasis Flaking, inflammation Thick, white, silvery, or red patches of skin Chronic condition
Pyoderma gangrenosum Purulent ulcer Ragged and violaceous border
Venous stasis ulcers
Traumatic ulcers
Bowen Disease Red scaly patch Very early form of skin cancer that is very treatable

referred to as squamous cell carcinoma insitu

Sebaceous Hyperplasia Lesions can be single or multiple lesions

Yellowish, soft, small papules on the face

Usually on the nose, cheeks, and forehead
Allergic Contact Dermatitis Itchy rash Red rash Not contagious
Atopic Dermatitis Itchy rash Fever Red rash Chronic and sometimes accompanied by asthma
Atypical Fibroxanthoma Erythematous, dome-shaped papule
Nevus
Chemical Burns
Limbal Dermoid Contains choristomatous tissue Benign congenital tumor
Benign hereditary intraepithelial dyskeratosis Rare autosomal-dominant disorder of the conjunctiva and oral mucosa
primary acquired melanosis
Fibrous xanthoma Containing fibromatous elements Arises due to disturbed systemic lipid metabolism
Inflamed seborrheic keratosis Inflamed and hyperpigmented On dermatoscopic evaluation, presence of horned cysts and hairpin-shaped blood vessels
Juvenile xanthogranuloma Reddened, yellowish-tan color of lesions Slightly raised bumps Typically
Cutaneous fungal infections
Desmoplastic trichoepithelioma
Adnexal carcinoma Very rare
Keratoacanthoma
Darier disease Keratosis follicularis
Cutaneous T-cell lymphoma Mycosis fungoides
Marjolin's ulcer Lesions in sites of chronic wounds and scars Excessive granulation tissue, Rolled or everted wound margins Bleeding on touch
  • rare type of SCC
  • Very slow malignant transformation
Epithelioma cuniculatum Increased size Verrucous carcinoma on the plantar foot
Anogenital also known as giant condyloma acuminatum of Buschke-Loewenstein
Keratoacanthoma Found on actinically damaged skin Rapid initial growth Dome-shaped or crateriform nodules with a central keratotic core Increased size keratocytic epithelial tumors